3 unchanged sentences
(c) Insider Trading Arrangements and Policies.
−Removed: During the three months ended March 31, 2026, no director or officer of the Company adopted or terminated a “ Rule 10b5-1 trading arrangement ” or “ non-Rule 10b5-1 trading arrangement ,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: On May 13, 2026 , Hunter Smith , the Company's Chief Financial Officer , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 62,774 shares of the Company's common stock as well as up to 100% of the shares of our common stock issued to Mr.
+Added: Smith upon the settlement of outstanding restricted stock units, less the number of shares surrendered to the issuer or sold to cover tax withholding obligations in connection with the vesting and settlement of such restricted stock units, until May 12, 2027 .
+Added: On May 13, 2026 , Yann Mazzabraud , the Company's Executive Vice President, Head of International , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 57,000 shares of the Company's common stock until August 15, 2027 .
+Added: On May 14, 2026 , Alastair Garfield , the Company's Chief Scientific Officer , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 7,763 shares of the Company's common stock until February 13, 2027 .
+Added: On May 14, 2026 , Jennifer Lee , the Company's Executive Vice President, Head of North America , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 76,201 shares of the Company's common stock as well as up to 100% of the shares of our common stock issued to Ms.
+Added: Lee upon the settlement of outstanding restricted stock units, less the number of shares surrendered to the issuer or sold to cover tax withholding obligations in connection with the vesting and settlement of such restricted stock units, until March 1, 2027 .
+Added: On June 15, 2026 , David Meeker , the Company's Chief Executive Officer , adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the sale of up to 300,000 shares of the Company's common stock until March 15, 2027 .
+Added: On June 24, 2026 , Lynn Tetrault , a member of the Company’s Board of Directors , terminated a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, which was previously adopted on December 15, 2025 and provided for the sale of up to 55,000 shares of the Company’s common stock until September 16, 2026.
+Added: Other than as disclosed above, during the three months ended June 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “ non-Rule 10b5-1 trading arrangement ,” as each term is defined in Item 408(a) of Regulation S-K.
Incorporated by Reference
10 unchanged sentences
10-Q 05/07/2024 3.4
−Removed: 4.1 F orm of Indenture
+Added: 4.1 Form of Indenture
2/26/2026 4.3
10.1* Rhythm Pharmaceuticals, Inc.
−Removed: Deferred Compensation P lan (Directors)
+Added: Non-Employee Director Compensation Program
+Added: 10.2* Severance Letter Agreement Dated June 25, 2026, between Rhythm Pharmaceuticals, Inc.
+Added: and Pamela Cramer
+Added: 10.3* First Amendment to Revenue Interest Financing Agreement dated March 27, 2024, between Rhythm Pharmaceuticals, Inc.
+Added: and HCR Rhythm SPV, LLC
+Added: 10.4* Second Amendment to Revenue Interest Financing Agreement dated June 29, 2026, between Rhythm Pharmaceuticals, Inc.
+Added: and HCR Rhythm SPV, LLC
31.1* Certification of the Principal Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C.
13 unchanged sentences
RHYTHM PHARMACEUTICALS, INC.
+Added: August 4, 2026
President and Chief Executive Officer
(Principal Executive Officer)
+Added: August 4, 2026
/s/ Hunter C.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.